Inflammation and cystic fibrosis pulmonary disease (Q34249405)

31 July 2017

1 reference

title

Inflammation and cystic fibrosis pulmonary disease (English)

1 reference

31 July 2017

0 references

Kennedy MJ

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

21

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

593-603

1 reference

Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Release of Interleukin-8, Interleukin-6, and Colony-stimulating Factors by Upper Airway Epithelial Cells: Implications for Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Effects of high doses of inhaled corticosteroids on adrenal function in children with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Effect of high-dose ibuprofen in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Relative underweight in cystic fibrosis and its prognostic value

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Regional Variability of Lung Inflammation in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592/PHCO.21.6.593.34546

10.1592/PHCO.21.6.593.34546

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference